Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Hepatology · Chronic Hepatitis B

Living with Chronic Hepatitis B: Long-term Monitoring and Cancer Prevention

At a Glance

Regular 6-month surveillance is essential for anyone living with chronic Hepatitis B, even if the virus is suppressed by medication. Routine abdominal ultrasounds and AFP blood tests are the most effective way to catch potential liver cancer early when it is highly treatable.

Living with chronic Hepatitis B means entering a long-term partnership with your medical team. The most critical part of this partnership is surveillance—the proactive, regular monitoring used to catch potential liver issues, specifically liver cancer (Hepatocellular Carcinoma or HCC), at their earliest and most treatable stages [1].

Why Monitoring Never Stops

It is a common misconception that if the virus is suppressed by medication and the viral load is “undetectable,” the risk of liver cancer disappears. While antiviral therapy significantly lowers the risk, it does not eliminate it completely [2][3].

The risk persists because the virus leaves behind genetic “blueprints” (cccDNA) and sometimes integrates itself into your liver cells’ own DNA [4][5]. For this reason, regular check-ups remain essential even if you feel perfectly healthy and your lab results look excellent [6].

The 6-Month Standard

Major medical organizations, including the AASLD and EASL, recommend that high-risk patients undergo surveillance every 6 months [7]. This interval is chosen because liver tumors, if they develop, tend to grow at a rate where a 6-month window is often enough to catch them while they are still small and manageable [8].

Surveillance typically involves:

  • Abdominal Ultrasound: A painless imaging test that uses sound waves to look for any unusual nodules or masses in the liver [8].
  • AFP (Alpha-Fetoprotein) Test: A blood test that measures a protein often produced by liver cancer cells. When used together with an ultrasound, it can help doctors get a clearer picture of your liver health [9][10].

Personalized Risk: The PAGE-B Scores

Not every patient has the same level of risk. To help personalize your monitoring plan, doctors often use a scoring system called PAGE-B or its updated version, mPAGE-B. These scores use simple data points to predict your risk of developing liver cancer over the next five to ten years [11][12].

Score Component Why it Matters
Age Risk naturally increases as we get older.
Gender Men with HBV statistically have a higher risk than women.
Platelets A low platelet count can be an early indicator of liver scarring (cirrhosis).
Albumin (mPAGE-B only) This protein made by the liver reflects how well the liver is functioning.

Patients with a low mPAGE-B score may be at very low risk, while those with a high score (typically 9 or above) require the most vigilant surveillance [13][14].

Managing “Scanxiety”

The process of waiting for a scan and then waiting for the results can cause significant psychological distress, often called scanxiety [15]. It is normal to feel a spike in anxiety every six months.

To manage this, remember that surveillance is a tool of empowerment. Catching a problem early is the most effective way to ensure a successful outcome [16]. If you find the stress overwhelming, talk to your doctor about support resources or mental health strategies to help you stay engaged with this life-saving routine [15]. Consistent monitoring is the best way to ensure that you stay ahead of the virus and continue to live a long, healthy life.

Common questions in this guide

Why do I need an ultrasound every 6 months if my Hepatitis B viral load is undetectable?
Even when antiviral medication successfully suppresses the virus, the risk of liver cancer does not completely disappear. The virus can leave behind genetic blueprints in your liver cells, making regular 6-month check-ups essential to catch any potential tumors early.
What does a PAGE-B or mPAGE-B score mean for my Hepatitis B care?
The PAGE-B and mPAGE-B scores are risk assessment tools doctors use to predict your chances of developing liver cancer over the next five to ten years. They use simple factors like your age, gender, platelet count, and albumin levels to personalize your monitoring plan.
Can an AFP blood test replace an ultrasound for liver cancer screening?
An AFP blood test should not replace your ultrasound. Instead, it is used alongside the ultrasound to measure a specific protein often produced by liver cancer cells, giving your doctor a more complete picture of your liver health.
How can I manage the anxiety before my 6-month liver scans?
It is entirely normal to experience "scanxiety" before routine check-ups. To help manage this stress, remember that consistent monitoring is a proactive tool that catches problems early, and do not hesitate to ask your medical team for mental health support resources.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my mPAGE-B score, which risk category (low, medium, or high) do I fall into?
  2. 2.Why do I still need an ultrasound every 6 months even though my viral load is undetectable?
  3. 3.Does my family history of liver cancer change the frequency or type of screening I should receive?
  4. 4.If an ultrasound shows something 'suspicious,' what are the next steps in my care plan?
  5. 5.Can we use AFP blood tests in addition to my ultrasound to increase the sensitivity of our screening?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    [Screening and surveillance for hepatocellular carcinoma in patients with chronic hepatitis B virus infection].

    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2021; (29(10)):932-941 doi:10.3760/cma.j.cn501113-20210927-00484.

    PMID: 34814387
  2. 2

    [Effect of antiviral therapy on the occurrence of hepatitis B-related hepatocellular carcinoma].

    Sun J, Zhang S, Wang YX, et al.

    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2019; (27(9)):721-724 doi:10.3760/cma.j.issn.1007-3418.2019.09.014.

    PMID: 31594101
  3. 3

    Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do.

    Abdelhamed W, El-Kassas M

    Liver research 2024; (8(2)):83-90 doi:10.1016/j.livres.2024.05.004.

    PMID: 39959873
  4. 4

    Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure.

    Yoo J, Hann HW, Coben R, et al.

    Diseases (Basel, Switzerland) 2018; (6(2)) doi:10.3390/diseases6020027.

    PMID: 29677098
  5. 5

    The impact of long-term potent antiviral therapy on the natural course of disease in patients with hepatitis B virus-related cirrhosis.

    Kilic G, Guvenir T, Bodakci E, et al.

    Hepatology forum 2025; (6(4)):141-145 doi:10.14744/hf.2024.2024.0069.

    PMID: 41122158
  6. 6

    Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.

    Tsai MC, Chen CH, Hu TH, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2017; (116(7)):512-521 doi:10.1016/j.jfma.2016.08.006.

    PMID: 27720344
  7. 7

    [Treatment of chronic hepatitis B virus infection and hepatocellular carcinoma prevention].

    Soudan D, Sultanik P, Pol S

    Presse medicale (Paris, France : 1983) 2015; (44(12 Pt 1)):1251-5.

    PMID: 26358671
  8. 8

    Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.

    Hwang SY, Danpanichkul P, Agopian V, et al.

    Clinical and molecular hepatology 2025; (31(Suppl)):S228-S254 doi:10.3350/cmh.2024.0824.

    PMID: 39722614
  9. 9

    Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.

    Tzartzeva K, Obi J, Rich NE, et al.

    Gastroenterology 2018; (154(6)):1706-1718.e1 doi:10.1053/j.gastro.2018.01.064.

    PMID: 29425931
  10. 10

    Serum Biomarkers for the Prediction of Hepatocellular Carcinoma.

    Debes JD, Romagnoli PA, Prieto J, et al.

    Cancers 2021; (13(7)) doi:10.3390/cancers13071681.

    PMID: 33918270
  11. 11

    Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.

    Kaneko S, Kurosaki M, Joko K, et al.

    Scientific reports 2020; (10(1)):13021 doi:10.1038/s41598-020-69522-w.

    PMID: 32747646
  12. 12

    External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy.

    Lee HW, Kim SU, Park JY, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2019; (39(9)):1624-1630 doi:10.1111/liv.14129.

    PMID: 31050379
  13. 13

    Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B.

    Sprinzl MF, Feist C, Koch S, et al.

    BMC health services research 2021; (21(1)):846 doi:10.1186/s12913-021-06794-6.

    PMID: 34419018
  14. 14

    Shifts in Cohort Eligibility With Deimplementation of Race-specific Guidance for Hepatocellular Carcinoma Surveillance.

    Macedo B, McDonald J, Dash A, et al.

    Gastro hep advances 2026; (5(1)):100773 doi:10.1016/j.gastha.2025.100773.

    PMID: 41127142
  15. 15

    Identifying Adherence Trajectories in Chronic Hepatitis B: A Cluster-Based Approach to Long-Term Treatment Management.

    Zhang L, Ji H, Pang S, et al.

    Journal of viral hepatitis 2025; (32(10)):e70068 doi:10.1111/jvh.70068.

    PMID: 40944469
  16. 16

    Consensus on the secondary prevention of primary liver cancer.

    Nan Y, Xu X, Gao Y, et al.

    Hepatology international 2021; (15(6)):1289-1300 doi:10.1007/s12072-021-10259-7.

    PMID: 34846705

This page provides educational information about Hepatitis B monitoring and liver cancer surveillance. Always consult your hepatologist or gastroenterologist for your personalized screening schedule and test result interpretation.

Get notified when new evidence is published on hepatitis B virus infection.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.